Duyuru • Jul 26
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite Index GreenLight Biosciences Holdings has been dropped from NASDAQ Composite Index (^COMP) . Reported Earnings • May 11
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$0.19 loss per share (improved from US$0.34 loss in 1Q 2022). Revenue: US$3.82m (up US$3.56m from 1Q 2022). Net loss: US$28.5m (loss narrowed 26% from 1Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US. Reported Earnings • Mar 30
Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat Full year 2022 results: US$1.27 loss per share (further deteriorated from US$1.17 loss in FY 2021). Net loss: US$167.1m (loss widened 49% from FY 2021). Products in clinical trials Phase I: 6 Phase II: 2 Post-clinical trial products Pre-registration: 2 Revenue exceeded analyst estimates by 156%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in the US. Duyuru • Feb 03
Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccine Platform Life Sciences signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that has been approved by the Rwanda FDA. The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa. Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products. The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases. Duyuru • Feb 02
Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine Candidate GreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Nov 11
Third quarter 2022 earnings released: US$0.27 loss per share (vs US$9.86 loss in 3Q 2021) Third quarter 2022 results: US$0.27 loss per share. Net loss: US$38.2m (loss widened 14% from 3Q 2021). Revenue is forecast to grow 121% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Recent Insider Transactions • Aug 17
Independent Director recently bought US$250k worth of stock On the 11th of August, Matthew Walker bought around 64k shares on-market at roughly US$3.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Aug 16
Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.28 loss in 2Q 2021) Second quarter 2022 results: US$0.42 loss per share (down from US$0.28 loss in 2Q 2021). Net loss: US$51.9m (loss widened 91% from 2Q 2021). Duyuru • Aug 13
GreenLight Biosciences Holdings announced that it expects to receive $109.149981 million in funding from a group of investors GreenLight Biosciences Holdings announced a private placement of 27,844,383 common shares at a price per share of $3.92 for gross proceeds of $109,149,981 on August 12, 2022. The transaction will include participation from accredited investors, existing institutional investors and new investors including Cummings Foundation, Inc., Endowment Arm, the FTX Foundation, Insud Pharma S.L.U., Rivas Capital LLC, Sigmas Group, SymBiosis Capital Management LLC, returning investors S2G Ventures, Bnp Paribas Funds - Ecosystem Restoration; a fund managed by BNPP Asset Management Luxembourg, Continental Grain Company Corp., Cormorant Asset Management, LP, Fall Line Capital, LLC, Morningside Ventures Limited, and certain directors and executive officers of the company. Duyuru • Aug 02
GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineering Run for mRNA Covid-19 Vaccine GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership. Since the announcement of the strategic partnership between GreenLight Biosciences and Samsung Biologics in late 2021, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months, demonstrating platform adaptability and scalability. GreenLight's process—from drug substance and lipid nanoparticle formulation to bulk drug product—can be completed in the same facility, an important capability. GreenLight's mRNA synthesis reaction had a titer of 12g/L at commercial scale and produced 650g of mRNA. The company's RNA platform allowed GreenLight to move from conceptualizing an mRNA vaccine to delivering released clinical trial material in less than two years. With the demonstration at Samsung, and with GreenLight's Covid booster vaccine clinical trial expected to start in 2022, GreenLight would be capable of supplying mRNA vaccine at a commercial scale. Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Jul 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • May 18
First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 loss in 1Q 2021) First quarter 2022 results: US$0.34 loss per share (down from US$0.27 loss in 1Q 2021). Net loss: US$38.2m (loss widened 49% from 1Q 2021). Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 23
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Mar 30
GreenLight Biosciences Appoints Barney Graham as Human Health Scientific Advisory Board GreenLight Biosciences announced Barney Graham to its Human Health Scientific Advisory Board. The former deputy director of the NIAID Vaccine Research Center, Dr. Graham is an immunologist, virologist, and clinical trials physician with an extensive background in basic and translational research applied to vaccine development. He is best known for his research on respiratory syncytial virus (RSV), influenza, coronaviruses, HIV, and other emerging viral diseases. Until his retirement last year, Dr. Graham was the chief of the Viral Pathogenesis Laboratory and Translational Science Core. He was named one of the world’s 100 most influential individuals and one of the Heroes of the Year in 2021 by Time magazine for his role in developing the COVID-19 vaccine. He was also recognized as the Federal Employee of the Year by the Partnership for Public Service. Dr. Graham is an author on more than 500 scientific publications and a thought leader on emerging viral diseases and pandemic preparedness. He was involved in the advanced evaluation of vaccines and monoclonal antibodies for HIV, Ebola, and Chikungunya. He also developed novel vaccines for RSV, influenza, Zika, paramyxoviruses, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody to enter clinical testing and that subsequently achieved Emergency Use Authorization and licensure. Duyuru • Feb 08
GreenLight Biosciences Holdings Announces Management Changes On February 2, 2022, Environmental Impact Acquisition Corp. (ENVI), consummated the previously announced business combination with GreenLight Biosciences Inc. (GreenLight), pursuant to the terms of the business combination agreement, dated August 9, 2021 (the Business Combination Agreement), among ENVI, GreenLight and Honey Bee Merger Sub Inc. (“Merger Sub). Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into GreenLight, with GreenLight surviving the merger as a wholly owned subsidiary of ENVI (the Merger or Business Combination). In connection with the consummation of the Merger on the Closing Date, ENVI changed its name to GreenLight Biosciences Holdings, PBC (GreenLight Holdings) and became a public benefit corporation. Effective upon the Closing, and in accordance with the terms of the Business Combination Agreement, each of Daniel Coyne, Marc Marano, Deval L. Patrick, David Brewster and Dean Seavers ceased serving as a director of GreenLight Holdings, and each of Daniel Coyne and Marc Marano ceased serving as an executive officer of GreenLight Holdings. Board Change • Feb 05
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Board Observer Colin Steen was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 